// App-Quantinova.ai

: Anti-CD 19 CAR-T Cell Therapy with Tisagenlecleucel for Ritcher Syndrome

Researchers

Presenter

  • Iloabueke Chineke

Principal Investigators

  • Muhammad Hassab

  • Abhijeet Kumar

  • Muhammad Husnain

Medical Centers

  • Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

  • University of Arizona Cancer Center, Division of Hematology and Medical Oncology, Tucson, AZ

  • Hematology/Medical Oncology, University of Arizona, Tucson, AZ

  • University of Arizona, Tucson, AZ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Cytokine release syndrome

  • B cell lymphomas

  • Hodgkin's Lymphoma

  • Lymphomas

  • Diffuse large B-cell lymphoma

Biomarkers

  • B-cell lymphoma 2

  • B-cell lymphoma 6

  • Cluster of Differentiation 19

  • Cluster of Differentiation 30

  • Twist-related protein 1

  • Tumor protein p53

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • tisagenlecleucel-t

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Tocilizumab

  • Adcetris

  • fludarabine tablet

  • Venetoclax

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved